Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

784

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

April 30, 2029

Conditions
Tuberculosis (TB)
Interventions
DRUG

Isoniazid (H)

H, weight based, 150-375mg

DRUG

Rifampicin (R)

R, weight based, 300-750mg

DRUG

Pyrazinamide (Z)

Z, weight based, 800-2000mg

DRUG

Ethambutol (E)

E weight based, 550-1375mg

Trial Locations (4)

Unknown

National University of Medical Sciences, Islamabad

Clinical HIV Research Unit, Wits Health Consortium, Johannesburg

The Aurum Institute, Johannesburg

Bulawayo City Health, Bulawayo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National University of Medical Sciences, Pakistan

OTHER

collaborator

Aurum Institute

OTHER

collaborator

Biomedical Research and Training Institute, Zimbabwe

OTHER

collaborator

Foundation for Innovative New Diagnostics, Switzerland

OTHER

collaborator

KTH Royal Institute of Technology

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

Wits Health Consortium (Pty) Ltd

OTHER

lead

University College, London

OTHER